Indeed, in gastric cancer tissue samples obtained following treatment by the CXCR1/2 inhibitor reparixin, reduced levels of proliferating tumor cells were noted, alongside with reduced presence of PD-L1+ macrophages and increased fraction of CD8+ T cells (121). Here, CD8A is linked to gastric cancer.